Last $123.52 USD
Change Today -0.84 / -0.68%
Volume 1.0M
As of 8:04 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

valeant pharmaceuticals inte (VRX) Key Developments

Valeant it has Filed a Complaint with Securities Regulators in Quebec and the U.S

Valeant said on July 21, 2014 it has filed a complaint with securities regulators in Quebec and the U.S. over allegedly unfair tactics by Allergan Inc. Valeant said it has contacted both the Autorité des marchés financiers and the U.S. Securities and Exchange Commission regarding Allergan's "apparent attempt to mislead investors and manipulate the market for Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements correcting such information. Valeant says Allergan falsely stated last Friday in an SEC filing that Valeant's Bausch + Lomb pharmaceutical sales were stagnant or declining, when in fact they grew about 6% in the second quarter. The U.S. prescription pharmaceutical business grew 17% over the year-earlier period, with the lion's share of that growth due to volume increases.

Galderma S.A. to Distribute Valeant Pharmaceuticals International, Inc.'s Products

Galderma S.A. announced that it has gained full rights to distribute Restylane(R), Perlane(R), Emervel(R), Sculptra(R) and Dysport(R) from Valeant Pharmaceuticals International, Inc. The expansion into aesthetic and corrective dermatology in the U.S. and Canada completes Galderma's global skin health footprint and extends its leadership in aesthetic medicine worldwide. Galderma will pursue to distribute the acquired products through the existing distribution partner. Healthcare practitioners are invited to continue to order products through their current account number and phone numbers. Beginning July 28, 2014 Galderma will have a new branded distribution process. All accounts will automatically receive a new Galderma account number and information on the new ordering process.

Valeant Pharmaceuticals International, Inc. Receives U.S. Food and Drug Administration Clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine

Valeant Pharmaceuticals International, Inc. announced that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Restylane(R) Silk Injectable Gel with 0.3% Lidocaine, a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21. Restylane Silk is a crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body. Restylane Silk is non-animal based and free from animal protein. Allergy pretesting is not necessary. Restylan Silk contains 0.3% lidocaine, which was added to reduce the discomfort associated with the treatment. Clinical study was conducted with Restylane(R) Silk to evaluate the safety and effectiveness of injections to enhance lip fullness and to improve the wrinkles around the lips. The study included 221 mostly female subjects and evaluated subjects with light and dark skin. Subjects with very dark skin were not studied. 98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection. The majority of adverse events were mild in intensity and the most common symptoms were lip swelling, contusion, and lip pain. The incidence of adverse event decreased significantly after the second treatment. Restylane Silk is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients with a history of allergies to gram positive bacterial proteins; patients with bleeding disorders; for implantation in anatomical spaces other than the dermis or submucosal implantation for lip augmentation and should not be used in patients with previous hypersensitivity to local anesthetics of the amide type, such as lidocaine.

Valeant Pharmaceuticals International, Inc. Announces Planned Departure of Ryan Weldon as Executive Vice President and Group Chairman

Valeant Pharmaceuticals International, Inc. (Valeant) announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant to Nestlé S.A. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma.

Valeant Pharmaceuticals International, Inc. - Special Call

To discuss recent misleading assertions made by Allergan, Inc. and others

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $123.52 USD -0.84

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $217.45 USD -1.23
Astellas Pharma Inc ¥1,402 JPY +2.00
Mylan Inc/PA $51.74 USD -0.16
Shire PLC 4,962 GBp -24.00
Sun Pharmaceutical Industries Ltd 782.20 INR +34.00
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.3x
Price/Book 8.2x
Price/Cash Flow 89.3x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.